Advertisement
Screener

ANIXA BIOSCIENCES, INC. (ANIX) Stockholders' Equity Attributable to Noncontrolling Interest

2.8 / 5 stars · 68/120 Roast Me

ANIXA BIOSCIENCES, INC. Stockholders' Equity Attributable to Noncontrolling Interest

ANIXA BIOSCIENCES, INC. (ANIX) had Stockholders' Equity Attributable to Noncontrolling Interest of -$1.27 million as of 2026-07-31, per its 10-Q filed 2026-09-09.

Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest

us-gaap:MinorityInterest · last filed 2026-09-09

  • 2026-07-31: Stockholders' Equity Attributable to Noncontrolling Interest -$1.27M.
  • 2026-04-30: Stockholders' Equity Attributable to Noncontrolling Interest -$1.25M.
  • 2026-01-31: Stockholders' Equity Attributable to Noncontrolling Interest -$1.23M.
  • 2025-10-31: Stockholders' Equity Attributable to Noncontrolling Interest -$1.21M.
Period endStockholders' Equity Attributable to Noncontrolling InterestStockholders' Equity Attributable to Noncontrolling Interest as first filed
2026-07-31-$1.27M
10-Q · filed 2026-09-09
2026-04-30-$1.25M
10-Q · filed 2026-06-10
2026-01-31-$1.23M
10-Q · filed 2026-03-09
2025-10-31-$1.21M
10-Q · filed 2026-09-09
2025-07-31-$1.18M
10-Q · filed 2025-09-10
2025-04-30-$1.16M
10-Q · filed 2025-05-28
2025-01-31-$1.14M
10-Q · filed 2025-03-11
2024-10-31-$1.11M
10-K · filed 2026-01-12
2024-07-31-$1.08M
10-Q · filed 2024-09-06
2024-04-30-$1.04M
10-Q · filed 2024-06-04
2024-01-31-$1.00M
10-Q · filed 2024-03-12
2023-10-31-$966.00K
10-K · filed 2026-01-12
2023-07-31-$935.00K
10-Q · filed 2023-09-06
2023-04-30-$898.00K
10-Q · filed 2023-06-14
2023-01-31-$879.00K
10-Q · filed 2023-03-17
2022-10-31-$847.00K
10-K · filed 2025-01-10
2022-07-31-$794.00K
10-Q · filed 2022-09-09
2022-04-30-$765.00K
10-Q · filed 2022-06-10
2022-01-31-$721.00K
10-Q · filed 2022-03-11
2021-10-31-$671.00K
10-K · filed 2024-01-16
-$670.51K
10-K · filed 2022-01-04
2021-07-31-$612.73K
10-Q · filed 2021-09-01
2021-04-30-$559.11K
10-Q · filed 2021-06-10
2021-01-31-$521.07K
10-Q · filed 2021-03-11
2020-10-31-$497.00K
10-K · filed 2023-01-04
-$496.98K
10-K · filed 2021-01-07
2020-07-31-$480.01K
10-Q · filed 2020-09-08
2020-04-30-$464.90K
10-Q · filed 2020-06-09
2020-01-31-$447.01K
10-Q · filed 2020-03-09
2019-10-31-$422.98K
10-K · filed 2022-01-04
2019-07-31-$399.41K
10-Q · filed 2019-09-06
2019-04-30-$373.39K
10-Q · filed 2019-06-12
2019-01-31-$336.14K
10-Q · filed 2019-03-13
2018-10-31-$251.38K
10-K · filed 2021-01-07
2018-07-31-$162.35K
10-Q · filed 2018-09-07
2018-04-30-$45.70K
10-Q · filed 2018-06-11
2018-01-31-$31.72K
10-Q · filed 2018-03-09
2017-10-31$0.00
10-Q · filed 2018-03-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
CITIUS ONCOLOGY, INC. (CTOR)United States$0.097B-1.49
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
Acrivon Therapeutics, Inc. (ACRV)United States$0.091B-1.03
ProMIS Neurosciences Inc. (PMN)$0.102B
Rallybio Corp (RLYB)United States$0.089B
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
ONCOLYTICS BIOTECH INC (ONCY)$0.086B
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)United States$0.086B
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
Lexaria Bioscience Corp. (LEXX)$0.084B-1.92